Abeona Therapeutics (ABEO)

• Market cap: $294M
• 1 day: -0.87%
• 5 days: -16.47%
• 1 month: -17.8%
• 3 months: -4.86%
• 6 months: 7.17%
• Year to date: -3.89%
• 1 year: 6.57%
• 5 years: -87.98%
• 10 years: -95.45%
• Sector: Healthcare
• Industry: Biotechnology

About: Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.

Employees: 136

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

504% more call options, than puts

Call options by funds: $14.7M | Put options by funds: $2.43M

133% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 18

131% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 13

40% more capital invested

Capital invested by funds: $141M [Q1] → $198M (+$57M) [Q2]

34% more funds holding

Funds holding: 71 [Q1] → 95 (+24) [Q2]

7.08% more ownership

Funds ownership: 61.14% [Q1] → 68.22% (+7.08%) [Q2]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $20
• Avg. target: $20
• High target: $20

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju	$20	Buy Reiterated	18 Aug 2025
Oppenheimer Andreas Argyrides	$20	Outperform Maintained	15 Aug 2025